Literature DB >> 17621180

Influence of verteporfin photodynamic therapy on inflammation in human choroidal neovascular membranes secondary to age-related macular degeneration.

Olcay Tatar1, Annemarie Adam, Kei Shinoda, Efdal Yoeruek, Peter Szurman, Silvia Bopp, Claus Eckardt, Karl Ulrich Bartz-Schmidt, Salvatore Grisanti.   

Abstract

PURPOSE: To examine the short- and long-term consequences of verteporfin photodynamic therapy (PDT) on inflammation with regard to infiltration of macrophages and leukocytes and expression of thy-1 in human choroidal neovascularization membranes (CNV) secondary to age-related macular degeneration (AMD).
METHODS: Retrospective review of an interventional case series of 43 patients who underwent removal of CNV. Twenty patients were treated with PDT 3 to 246 days preoperatively. Twenty-three CNV without previous treatment were used as control. CNV were stained for CD34, CD105, cytokeratin 18, Ki-67, thy-1, an endothelial cell glycoprotein known to be upregulated only by inflammatory cytokines, CD68 (macrophages), and CD45 (common leukocyte antigen).
RESULTS: Specimens treated by PDT 3 days previously showed significantly reduced endothelial thy-1 expression (P = 0.008), leukocyte (P=0.04) and macrophage (P=0.0063) infiltration, and proliferative activity (P=0.02) compared to control CNV. Specimens at longer intervals after PDT, in contrast, disclosed a significantly increased expression of thy-1 (P=0.004), infiltration with leukocytes (P=0.044) and macrophages (P=0.01), and proliferative activity (P=0.03) compared to CNV excised 3 days after PDT.
CONCLUSIONS: The rebound effect after PDT seems to be based on an inflammatory response that contributes to enhanced proliferation. These data support the need for an anti-inflammatory therapy as adjuvant to PDT.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17621180     DOI: 10.1097/IAE.0b013e318042d3b0

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  12 in total

1.  The YAP1 Signaling Inhibitors, Verteporfin and CA3, Suppress the Mesothelioma Cancer Stem Cell Phenotype.

Authors:  Sivaveera Kandasamy; Gautam Adhikary; Ellen A Rorke; Joseph S Friedberg; McKayla B Mickle; H Richard Alexander; Richard L Eckert
Journal:  Mol Cancer Res       Date:  2019-11-15       Impact factor: 5.852

2.  Matrix metalloproteinases in human choroidal neovascular membranes excised following verteporfin photodynamic therapy.

Authors:  Olcay Tatar; Annemarie Adam; Kei Shinoda; Tillmann Eckert; Gábor B Scharioth; Micheal Klein; Efdal Yoeruek; Karl Ulrich Bartz-Schmidt; Salvatore Grisanti
Journal:  Br J Ophthalmol       Date:  2007-05-02       Impact factor: 4.638

3.  Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration.

Authors:  Farzin Forooghian; Catherine Cukras; Catherine B Meyerle; Emily Y Chew; Wai T Wong
Journal:  Retina       Date:  2009-06       Impact factor: 4.256

4.  Lucentis using Visudyne study: determining the threshold-dose fluence of verteporfin photodynamic therapy combined with intravitreal ranibizumab for exudative macular degeneration.

Authors:  Eric Chen; David M Brown; Tien P Wong; Matthew S Benz; Eric Kegley; Joel Cox; Richard H Fish; Rosa Y Kim
Journal:  Clin Ophthalmol       Date:  2010-10-05

Review 5.  Combination of photodynamic therapy and immunomodulation: current status and future trends.

Authors:  Yong-Gang Qiang; Christine M N Yow; Zheng Huang
Journal:  Med Res Rev       Date:  2008-07       Impact factor: 12.944

6.  The effect of clonidine on VEGF expression in human retinal pigment epithelial cells (ARPE-19).

Authors:  Kazuhiko Watanabe; Xue-Yun Zhang; Kiyotaka Kitagawa; Tatsuya Yunoki; Atsushi Hayashi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-11-15       Impact factor: 3.117

7.  Effect of photodynamic therapy (PDT), posterior subtenon injection of triamcinolone acetonide with PDT, and intravitreal injection of ranibizumab with PDT for retinal angiomatous proliferation.

Authors:  Saya Nakano; Shigeru Honda; Hideyasu Oh; Mihori Kita; Akira Negi
Journal:  Clin Ophthalmol       Date:  2012-02-20

Review 8.  Macrophage targeted theranostics as personalized nanomedicine strategies for inflammatory diseases.

Authors:  Sravan Kumar Patel; Jelena M Janjic
Journal:  Theranostics       Date:  2015-01-01       Impact factor: 11.556

9.  The small tellurium-based compound SAS suppresses inflammation in human retinal pigment epithelium.

Authors:  Rima Dardik; Tami Livnat; Gilad Halpert; Shayma Jawad; Yael Nisgav; Shirley Azar-Avivi; Baoying Liu; Robert B Nussenblatt; Dov Weinberger; Benjamin Sredni
Journal:  Mol Vis       Date:  2016-05-28       Impact factor: 2.367

10.  The Features of Inflammation Factors Concentrations in Aqueous Humor of Polypoidal Choroidal Vasculopathy.

Authors:  Jie Hu; Xuan Leng; Yijun Hu; Alp Atik; Xin Song; Zhixi Li; Yuhua Liu; Lin Lu
Journal:  PLoS One       Date:  2016-01-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.